Lisavienna Newsletter 1-2016

Connecting Life Sciences

Highlights 01/2016

Life Science City Vienna: Broad Expertise on Infectious Diseases

page 3

Made in Vienna: Electromechanical Medical Devices

page 7

Biopharma is growing in Vienna Boehringer Ingelheim invests half a billion euros in its biopharmaceutical production capacities in Vienna. The new large-scale biopharmaceutical facility will allow production of active ingredients using cell cultures as of 2021 to meet growing in-house and contract manufacturing demands. Some 400 new jobs will be created. The Boehringer Ingelheim group is amongst the world’s 20 leading pharmaceutical companies. Its Regional Center Vienna is responsible for business and clinical research in more than 30 countries in Central and Eastern Europe, Central Asia, Israel and Switzerland. Modern facilities for biopharmaceutical research, development and production as well as Boehringer Ingelheim’s cancer research center are also located here. In total, Boehringer Ingelheim employs more than 3,400 people in the region, some 1,500 of these in the Austrian capital city.

Farbe/colour: PANTONE 288 CV

Oncology meets immunology Boehringer Ingelheim’s research center in Vienna has been dedicated to cancer research in 2000. So far, two innovative treatments developed in Vienna for non-small cell lung cancer as well as one for idiopathic pulmonary fibrosis have successfully entered the market. Annual research expenditures amount to 200 million euros and at the end of 2015, a new lab building was opened, housing 80 researchers working on immunotherapeutic approaches for various types of cancer. In 2015, Boehringer Ingelheim RCV started the construction work for a new research building dedicated to the Research Institute of Molecular Pathology (IMP) with an investment of 50 million euros.

Research beyond borders In the next five years, Boehringer Ingelheim will invest 11 billion euros worldwide to accelerate the discovery of next generation medical breakthroughs. This involves integrating internal and external insights and opportunities. Boehringer Ingelheim has established the organizational structures required for its new truly global and open innovation strategy. The company will collaborate with external partners along the entire R&D value chain and go beyond its core therapeutic areas when addressing unmet medical needs. www.boehringer-ingelheim.at www.imp.ac.at

Dear readers! The city of Vienna renewed its commitment for the life sciences in its new strategy paper on innovation and by publishing a new concept on how to make Vienna’s hospitals ready for the future. One core activity is to strengthen the Medical University of Vienna and the Vienna General Hospital. Together with the Austrian Federal Government, 2.2 billion euros will be invested through 2030. Commercial partners are welcome to profit from the clinical expertise available in Vienna’s 27 hospitals. Life sciences are booming in Vienna. We are delighted to update you on Boehringer Ingelheim’s decision to invest heavily in new production facilities in the city, about Nabriva Therapeutics going IPO, Marinomed and Panoptes closing financing rounds, and many other highlights. During the last months, new biotech products have for example been launched by the enzyme-specialist Eucodis and by Lexogen. One of the most important topics biotech companies in Vienna address is infectious diseases. Receive insights about clinical stage products and promising technology platforms by reading our article on page 3. For a who’s who in the development of electromechanical medical devices in Vienna, please check out page 6. Vienna is Austria’s most important place for the life sciences – from research and teaching through to the commercial biotech sector and the pharmaceutical and medical device industries. Meet the LISAvienna staff and connect with potential partners. Our technology experts also provide you with an overview on lab space available for rent in Vienna and are happy to discuss opportunities for funding and support that meet your requirements. In this regard, we also invite you to profit from the link lists at www.LISAvienna.at. But for now, enjoy reading and remember: Starting-up in Vienna pays off.

Peter Halwachs and Johannes Sarx LISAvienna Executive Board

LISAvienna – Connecting Life Sciences LISAvienna is the joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Science, Research and Economy and the city of Vienna, it contributes to the advancement of life sciences in Vienna. LISAvienna supports innovative biotech, pharmaceutical and medical technology companies in Vienna that develop and market new products, services and processes. The platform links these companies with development partners and key customers. As a central knowledge carrier, LISAvienna provides input for decisions to advance the life sciences in Vienna and contributes to positioning the city of Vienna as one of the leading European innovation centers. Please visit our website www.LISAvienna.at to learn more about Vienna as a top location for life sciences!

Our Services Information & Consulting:

Tips and contacts relating to sponsorship, private financing options, lab space in Vienna, development partners, leading customers and internationalization

Networking & Matching:

Contacts for an improved exchange of experiences and knowledge transfer as well as contact with development partners, leading customers and investors worldwide

Expertise:

Life Sciences in Vienna at a Glance • 480 organizations • 35,730 employees • 9.9 billion euros revenues • 32,870 students • 4,800 publications Vienna offers an ideal environment for the development of novel ideas and technologies into thriving businesses. We invite you to profit from leading global life science companies, successful startups, world-renowned academic institutions and top-class hospitals when starting-up in Vienna. Tailored funding and support opportunities are available to make your visions come true! Learn more about the life science city Vienna! Download the Vienna Life Science Report at www.LISAvienna.at and be invited to order your free print copy at office@LISAvienna.at.

Analyses, background information, reports and studies relating to life sciences in Vienna

Marketing:

Electronic and printed news items from the field of life sciences in Vienna

10 times a year: LISAvienna e-Newsletter Stay updated on hottest news from the life science city Vienna! Subscribe at www.lisavienna.at/en/e_newsletter

Life Science City Vienna: Broad Expertise on Infectious Diseases Vienna is Austria’s driving force for the medical biotechnology and pharmaceutical industry. A clear focus rests on infectious disease, cancer, diseases of the respiratory system and immunological disorders. At the end of September 2015, Nabriva Therapeutics AG announced the closing of its Initial Public Offering at NASDAQ, taking the regional antiinfectives business center stage. Some 20 dedicated biotech companies are focusing on infectious diseases in Vienna. Some of them offer diagnostics and related services while others provide niche services to pharmaceutical manufacturers worldwide. However, most of the companies strive for the prevention and treatment of serious infections. Selected clinical-stage drug candidates grounded in a broad range of technologies are introduced in the table. Many of them have been conceptualized at the Vienna Biocenter or in its close vicinity. Several companies included in the overview have promising technology platforms at hand that are open for collaborating to develop new products: • EB66® (Valneva): Cell line for the production of human and veterinary vaccines • IC31® (Valneva): Synthetic vaccine adjuvant • Mavirex (Marinomed): Anti-viral technology platform • Themaxyn (Themis Biosciences): Measlesvirus-vaccine based vaccine vector • Vaxwave (Hookipa Biotech): Replicationdefective viral vector for vaccine delivery

“

Why Vienna? Vienna has become an increasingly important location for biotech companies in Europe. In particular the public funding opportunities like the research premium have created an attractive environment for R&D companies and their investors. The city’s excellent infrastructure, as well as the high quality of life, has made attracting local and international talent and management increasingly easier over the past few years.”

Ralf Schmid, COO and CFO, Nabriva Therapeutics AG

Highlights 01/2016

Selected clinical-stage drug candidates: Company

Drug candidate

Indication

Status

Arsanis Biosciences GmbH www.arsanis.com

ASN100: Preventive and therapeutic antibody combination neutralizing cytotoxins

Staphylococcus aureus

Phase I ongoing

Hookipa Biotech AG www.hookipabiotech. com

HB101: Vaccine for immunization and immunotherapy

Cytomegalovirus (CMV)

Phase I to start in 2016

Marinomed Biotechnologie GmbH www.marinomed.com

Carraflu

Influenza

Ready for Phase IIa

Nabriva Therapeutics AG www.nabriva.com

Lefamulin (BC-3781): Small molecule pleuromutilin antibiotic; IV to oral

Community Acquired Bacterial Pneumonia (CABP); incl. multidrug resistant bacteria

IV/Oral Phase III initiated; Oral Phase III initiation planned Q1 2016

Lefamulin (BC-3781): small molecule pleuromutilin antibiotic; IV to oral

Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Phase II complete

BC-7013: Small molecule pleuromutilin antibiotic for topical use

Uncomplicated Skin and Skin Structure Infections (uSSSI)

Phase I complete

Panoptes Pharma GmbH www.panoptes-pharma. com

PP-001: Anti-inflammatory and anti-viral small molecule drug

Uveitis, adenoviral conjunctivitis and dry eye disease

Phase I to start in 2016

Themis Bioscience GmbH www.themisbio.com

Prophylactic vaccine based on a measles virus vaccine vector

Chikungunya virus

Phase II ongoing

Valneva Austria GmbH www.valneva.com

VLA43: Preventive vaccine; co-development with GSK

Pseudomonas aeruginosa

Phase II/III ongoing, data release in Q2 2016

VLA84: Preventive vaccine

Clostridium difficile

Phase II finished*

VLA15: Preventive vaccine

Lyme borreliosis

Phase I to start in H2 2016

deltaFLU: Live attenuated vaccine which lacks NS1 activity; nasal spray

Seasonal Influenza

Phase II ongoing

Vivaldi Biosciences AG www.vivaldibiosciences. com

For clinical stage projects in other areas please see the Vienna Life Science Report 2015/16 (table 3, p 28). *final study close-out in Q2 2016

ew investgie GmbH: N tion lo o n h c te io B Marinomed lobal expansion & innova g d ment boosts s” has acquire elstandsfond

. nd “aws Mitt ancial means investment fu significant fin The Austrian ts for d is providing en an m ny at pa tre m ’s co arinomed a share in the al roll-out of M velopment of lerate the glob intensify the de w lo al This will acce d an es as se di em based on enza-like spiratory syst cold and influ ions of the re ct fe in al vir r ts fo form. further produc chnology plat MAVIREX© te ry ta rie op pr the

Bulletin d Boar

ed.com www.marinom

: Antibody drug conEucodis Bioscience GmbH r technology shows jugate using CTATTM linke aft trial superior efficacy in xenogr

Correlated Multimodal Imaging Node Austria (CMI) to start operations The new platform unites imaging experts at leading research institutions throughout Austria. It offers quick and easy access to cutting edge imaging facilities for applications in the life sciences and is dedicated to the development of new technologies. CMI is coordinated by MedUni Vienna and the Vienna Biocenter Core Facilities GmbH. It aims at becoming

for conjugating difenzymatic linker technology CTATTM is an innovative their specificity, binding ibodies, without affecting ferent payloads with ant trial, the tested CTATthe presented xenograft properties or stability. In lly available ADC. rcia acy versus a comme ADC showed superior effic

part of the EuroBioImaging project.

www.eucodis.com

www.bioimaging-austria.at Scanning electron micrograph of a fruit fly head

WWTF: 6.2 millio new research gr n euros granted to tional biology anoups in computafocusing on cognd research projects itive sciences

The Vienna Science and Technology Fu nd (WWTF) promotes science and research in Vie nna. Since 2003, it provides substantia l support for the life sciences and other core research topics in Vienna. Recentl y, WWTF funding allowed to start five top-class projects in cognitive science and enabled the rec s ruiting of two outst anding young researchers in comp utational biology.

www.wwtf.at

OncoQR’s breast cancer vaccine successfully completes pre-clinical proof-of-concept study OncoQR ML, a company developing adjustable cancer immunotherapies, has announced that its breast cancer vaccine candidate OQR200 has successfully completed a proof-of-concept study in non-human primates (NHPs). In the study, the vaccine elicited the expression of very high levels of polyclonal antibodies targeting multiple epitopes on Her2/neu. www.oncoqr.com

Get connected @

(@lifesciencevie)

a n n e i V

Miracor M benefits edical Systems GmbH: P more and iCSO more pa Miracor M tients edical Sys tem

s markets coronary sinus inte the PiCSO rvention d ® Impuls size, and esigned to e System prevent th , the first improve c e develop and only ardiac fun infarction m ent of hea ction, red . The syst rt fa uce infarc e ilu m re is following currently Middle Ea t acute myo used in th st. e EU and cardial selected countries www.mira in the cormedic al.com

h-tech award ig h e iv e c e r bH to TAmiRNA Gm tech” tegory “high-

ca t prize in the arded the 1s GEWINN aw en be s nu ha an al 2015 d TAmiRNA tegory in the ca l ra been grante ne s ge ha in the the company , is th and 2nd prize to t r io en Pr r developm mer Award. r its biomarke of Jungunterneh e 1 funding fo e predictive as ph E As SM RN that ar Horzon2020 ulating micro rc ci d oo bl sing on program focu sal women. postmenopau in k ris e fractur a.com www.tamirn

SCARLETRED Holding GmbH & Silicon Valley

Under co Researchnstruction: New h (IMP) at th Institute of Mole ome for the cu e Vienna Biocente lar Pathology r

lected for tes in Vienna se itu st in w ne o LBG: Tw

SCARLETRED has celebrated the CE registration of its first commercial product Scarletred®Vision within Medic al Device Class 1. Besides receiving the Futurezone Award 2015 for the best App of the year, the company has been awarded as the most disruptive MedTech newcomer by the US Plug And Play Busine ss Accelerator in the course of WKO`s “Go Silicon Valley” progra m. Currently, the company seeks to raise 1.5M Euros in a Series A financing round. www.scarletred.at

funding

rch independent resea ft (LBG) is Austria’s ha llsc se nGe co nn ma d-class research The Ludwig Boltz h sciences. Worl ovation. focus on the healt ty and promote inn cie incubator with a so rve se st mu rs ste ll tes and clu g: One institute wi ducted in its institu selected for fundin en be ve ha in tes ze w institu er one will speciali Recently, two ne eases and the oth undiagnosed dis d an e rar on us foc s. applied diagnostic

www.lbg.ac.at

TU Wien: Innovation Center on the rise aws JumpStart funding allows the TU Wien to significantly extend the services offered at the Informatics Innovation Center (i2c). In 2012, it started as an initiative of the Faculty of Informatics implementing innovation. Cross-faculty programs have evolved early on and in 2015, the process of opening up all programs has started. Now, i2c will become a truly cross-faculty Innovation Center at TU Wien. http://i2c.ec.tuwien.ac.at

More news For more news please visit our website www.LISAvienna.at

Highlights 01/2016

ia d Conidion n a b a t L llabora tibody evelThe An nce start co assay d ility and ib s. s a e fe g Bioscie t ti an n duc

on tary proprie ab will c ells fuel specific tibody L ’s s and s ia re id n The An tu o c C fa n u o n hin a t work tion wit lops, m opmen ntamina ce deve o n c l ie ercial a c m s ic Bio est com robiolog rg ic Conidia la m t ’s c eet d rl te urface fl the wo hich de cludes rs and s tests w in le d ts n n a lie h . Its c ship c minutes owned sites. bally ren cultural lo g , s d e n a agri d airlin a ro il, cross ra users a om dylab.c eantibo h .t w w w

Your news placed here

Vienna-based organizations are invited to e-mail news and press releases to news@LISAvienna.at to contribute to LISAvienna’s digital and print media.

Business Location Vienna. The ideal location provides the best foundation. The Vienna Business Agency therefore supports relocating and expanding companies. Apply now for your funding at viennabusinessagency.at Vienna supports economy.

Meet LISAvienna • BIO-Europe Spring Stockholm, April 4-6, 2016

50.000 Euro

• BioProcess International European Summit Vienna, April 11-14, 2016

aws Temporary Management Financing of complementary management expertise www.awsg.at/maz

• CMEF Spring 2016 Shanghai, April 17-20, 2016 • conhIT 2016 Berlin, April 19-21, 2016 • BioTrinity 2016 London, April 25-27, 2016

800.000 Euro aws Seedfinancing Financing the start-up phase of life science companies www.seedfinancing.at

• Deutsche Biotechnologietage 2016 Leipzig, April 26-27, 2016 • BIO International Convention San Francisco, June 6-9, 2016 • The European Forum for Industrial Biotechnology and the Bioeconomy Glasgow, October 18-20, 2016

200.000 Euro aws PreSeed Financing the pre-start phase www.preseed.at

• BIO-Europe 2016 Cologne, November 7-9, 2016

We bring Life Sciences to Life www.lifescienceaustria.at

• Medica 2016 Düsseldorf, November 14-17, 2016 in cooperation with:

Made in Vienna: Electromechanical Medical Devices More than 200 medical device companies are located in Vienna. In 2014, these generated around 3.2 billion euros in revenues and employed almost 8,200 people. 16% of Vienna’s medical device companies perform research, development and manufacturing. One of the most important focus areas are electromechanical medical devices for the future.

Therapeutic devices Below, six companies creating new therapeutic medical devices in Vienna are presented. Learn more about their focus and be invited to connect. Carl Reiner GmbH has developed the jet ventilation system for ear, nose and throat surgeries. In 2011, the TwinStream has been made ready for the most critical patients in intensive care ventilation. Carl Reiner’s top class devices are available in >25 countries and established the company as world leader in tubeless ventilation.

Otto Bock Healthcare Products GmbH has developed the first completely microprocessorcontrolled lower limb prosthesis system in the world. Ottobock is a market leader in medical technology focusing on arm and leg prostheses, and also covers orthotics, mobility solutions and neuro-rehabilitation.

piur imaging GmbH develops tomographic ultrasound solutions for the safe and cost-efficient diagnosis of vascular diseases. It speeds up vascular ultrasound examinations, improves communication among physicians, and reduces the need for expensive and potentially harmful CT and MR examinations.

Repuls Lichtmedizintechnik GmbH offers a device for photo-medical pain treatment for acute and chronic diseases. Improved quality of life is achieved by applying the most modern LED technology with cold red light.

VASEMA GmbH has developed the world’s first non-invasive, quick and objective skin analyzer for measuring transepidermal water loss. DermaMeter is certified as class IIa medical product and is applied for the prevention and diagnosis of skin diseases and for monitoring wound healing.

Diagnostic tools The following five companies have developed particularly innovative electromechanical medical devices for diagnostic purposes in Vienna. Get in touch and discuss opportunities for collaboration.

Dr. Schuhfried Medizintechnik GmbH is a pioneer in electrostimulation in physical medicine. User-friendly products help patients suffering from dorsal pain with mobility. A special device for the stimulation of denervated muscles contributes to avoid the degeneration of muscles.

Derma Medical Systems GmbH is the world leader in dermoscopy, an expert in skin imaging and documentation. The company developed the first digital epiluminescence system in the world, which is now used in over 50 countries by the most advanced clinics and private dermatologists.

Miracor Medical Systems GmbH has developed the so-called PiCSO Impulse System. The system is used during percutaneous coronary intervention (PCI) in myocardial infarction patients to improve the clinical outcome by increasing myocardial perfusion and salvaging myocardium.

Dr. Grossegger & Drbal GmbH is a pioneer in the digital EEG field. Its alpha trace range of products stands for cutting-edge equipment in the field of neurology, neurophysiology and sleep medicine and has convinced numerous hospitals and private practices throughout the world.

Orthorobot Medizintechnik GmbH has specialized in precisely manufactured invisible dental braces. The experts for individual, fixed braces ship to orthodontists all over the world and provide a solution that allows exact positioning of the brackets and arch wires bent by highly accurate robots.

EMTensor GmbH is an expert regarding technologies for fast brain functional imaging, which is applied for mobile-diagnosis of stroke. The compact-size devices use the properties of how electromagnetic waves spread in tissues for medical imaging.

www.alphatrace.at www.carlreiner.at www.dermamedicalsystems.com www.emtensor.com www.miracormedical.com www.orthorobot.com www.ottobock.at www.piurimaging.com www.repuls.at www.schuhfriedmed.at www.vasema.com

Integrating know-how from electrical and mechanical engineering, material sciences, medicine and increasingly also from informatics is an essential prerequisite for success in this highly demanding business. In this article, we introduce selected companies that are major players in this field.

“

Lars Schiemanck, CTO and Managing Director at Miracor Medical Systems GmbH

Vienna is a great place for medical device companies. The city itself attracts talents from across Europe and its Medical and Technical Universities are a huge source for clinical and technical innovation and research.”

News strategy plan:

Medical University of Vienna and the Vienna General Hospital The Vienna General Hospital is one of Europe’s largest clinics and closely intertwined with the Medical University of Vienna, one of the world’s leading medical universities. 2.2 billion euros will be invested until 2030 to bring medicine to the next level: A new strategy plan and first-class equipment and facilities will benefit patients, research and teaching at Austria’s most important healthcare institution.

iversity

Medical Un of Vienna

loyees

p • 4,196 em

ents

ud • 7,500 st

ersity s and univ al institute • 30 clinic ts and departmen centers ical science • 12 med tments and depar osals study prop al research e ic te it in m cl m 0 o 13 C ics • 1, to the Eth submitted

and are open to collaboration. Five outstanding research clusters have been established, focusing on immunology, cancer, medical neuroscience, medical imaging and cardiovascular diseases. For looking beyond common diseases, the Vienna Center for Rare and Undiagnosed Diseases has been set up together with CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, as a core contact.

www.akhwien.at www.meduniwien.ac.at

Investing in new facilities

Expertise awaits partners

MedUni Vienna runs more than ten core facilities to support research. These range from biobanking, engineering and imaging services to genomics, proteomics and statistics. Until 2024, the city of Vienna and the Austrian Federal Government will provide 495.8 million euros for the purchase of new equipment and for the necessary upgrades

MedUni Vienna is the perfect partner for conducting all stages of clinical trials in almost any indication. A Clinical Trials Coordination Center facilitates access to experienced partners and stands for professional management of clinical research endeavors. In addition, basic medical research and technology development have a long tradition

Why Vienna?

Michaela Fritz, Vice Rector for Research and Innovation at the Medical University of Vienna

“

Vienna is a great place for life sciences since several world leading academic institutes, applied research organisations, universities and Europe’s largest hospital are grouped in close vicinity. The Medical University of Vienna stands for excellence in education, research and patient care and our physicians strive to bring innovation from the lab to the patient. To do so we are engaged in many national and international co-operations with other universities, institutes, clinics and companies and are looking forward to expand our network.”

crevo.net

of research facilities. By 2030, a total of 1.4 billion euros will have, for example, created high-end operating rooms, first-class emergency and accident facilities, a family center and innovative care strategies. A whole new building will be dedicated to translational medicine at the joint campus of MedUni Vienna and the Vienna General Hospital: 100 million euros will prepare the grounds for a place to develop new approaches for the prevention, diagnosis and treatment of diseases in Vienna. Tomorrow’s entrepreneurs will find a perfect place for their life science companies at a special startup center at the campus. It is furthermore envisioned to build a center for precision medicine and a technology transfer center where industry and start-ups can find a perfect place at the campus to interact with the university and the hospital.

The city of Vienna and the Austrian Federal Government have agreed on major investments to make the MedUni Vienna and the Vienna General Hospital fit for the future. The 650-year medical history at MedUni Vienna is unique throughout Europe. Its future will continue along this path. New rector Markus Müller and his team of vice-rectors are committed to high-end medicine. Providing a long-term perspective for healthcare and research is linked to new governance structures and an improved allocation of tasks between medical doctors and other professional groups. In the future, medical doctors will spend on average at least 30 percent of their working hours on teaching and research. Such major organizational innovations will accelerate pushing back the frontiers of knowledge.

LISAvienna Life Science Austria Vienna Walcherstrasse 11A 1020 Vienna, Austria

PHONE FAX E-MAIL WEB

+ 43 (0) 1 50175 358 + 43 (0) 1 50175 900 office@LISAvienna.at www.LISAvienna.at

LISAvienna is the joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Science, Research and Economy and the city of Vienna, LISAvienna contributes to the advancement of life sciences in Vienna.